Scarica l'app Stockscreener
93.00
0.81%
0.75
Dopo l'orario di chiusura:
93.01
0.01
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$92.25
Aprire:
$94.19
Volume 24 ore:
1.55M
Relative Volume:
1.36
Capitalizzazione di mercato:
$23.52B
Reddito:
$3.26B
Utile/perdita netta:
$-1.45B
Rapporto P/E:
-15.84
EPS:
-5.871
Flusso di cassa netto:
$1.18B
1 W Prestazione:
+2.92%
1M Prestazione:
-8.88%
6M Prestazione:
-9.44%
1 anno Prestazione:
-5.63%
Intervallo 1D:
$92.72
$95.84
Intervallo di 1 settimana:
$89.79
$95.84
Portata 52W:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
93.00 | 23.33B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
437.22 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.74 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
820.63 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.00 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-06-05 | Reiterato | H.C. Wainwright | Buy |
| 2025-05-29 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-01-10 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-11-19 | Iniziato | Berenberg | Buy |
| 2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-14 | Iniziato | Evercore ISI | In-line |
| 2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-05 | Iniziato | Oppenheimer | Perform |
| 2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
| 2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-17 | Iniziato | Cowen | Market Perform |
| 2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-16 | Downgrade | Redburn | Neutral → Sell |
| 2021-05-18 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-08-03 | Ripresa | Berenberg | Buy |
| 2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
| 2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Downgrade | UBS | Buy → Neutral |
| 2019-11-05 | Iniziato | Wolfe Research | Outperform |
| 2019-11-04 | Iniziato | Berenberg | Buy |
| 2019-11-04 | Iniziato | BofA/Merrill | Buy |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-11-04 | Iniziato | JP Morgan | Overweight |
| 2019-11-04 | Iniziato | SVB Leerink | Outperform |
| 2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk - Investing.com
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
BioNTech Faces Twin Test: Labor Strife Over 1,860 Jobs Meets ASCO’s Clinical Verdict () - aktiencheck.de
BioNTech Unveils $1B Buyback While Bernstein Flags Approval Risk Ahead of Oncology Data Dump - aktiencheck.de
symbol__ Stock Quote Price and Forecast - CNN
BioNTech’s ctDNA Colorectal Cancer Study Signals Next Steps in Its Oncology Strategy - TipRanks
BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung - GlobeNewswire Inc.
BNTX Technical Analysis | Trend, Signals & Chart Patterns | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Bernstein initiates BioNTech stock coverage citing pipeline concerns - Investing.com
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Nobel Laureate Karikó to Speak as BioNTech Cuts 1,860 Jobs in Oncology Pivot () - aktiencheck.de
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM - Yahoo Finance
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029? - TradingView
BioNTech authorizes $1 billion share buyback program By Investing.com - Investing.com South Africa
BioNTech authorizes $1 billion share buyback program - Investing.com
BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides - Barchart.com
BioNTech Earnings: Clinical Development on Track, Busy Schedule for the Remainder of the Year - Morningstar
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth - sharewise.com
BioNTech Q1 Earnings Call Highlights - Yahoo Finance
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides - ChartMill
BioNTech earnings ahead: Can oncology offset plunging vaccine sales? - Investing.com
Mitsubishi UFJ Trust & Banking Corp Sells 92,271 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pictet Asset Management Holding SA Buys 26,119 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s Cancer Pivot Faces a Defining Week as Founders Head for the Door () - aktiencheck.de
SanDisk, Western Digital, Clorox And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
BioNTech (NASDAQ:BNTX) Shares Gap DownWhat's Next? - MarketBeat
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
BioNTech SE Sponsored ADR $BNTX Shares Sold by Flossbach Von Storch SE - MarketBeat
Tangible book value per share of BioNTech SE Sponsored ADR – XETR:22UA - TradingView
BioNTech's $5.5 Million Insider Sale Precedes a Pivotal May for the Biotech () - aktiencheck.de
BioNTech SE (BNTX) Stock Price, Trades & News - GuruFocus
BioNTech SE (MEX:BNTXN) Stock Price, Trades & News - GuruFocus
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings? - TradingView
Sierk Poetting Sells 50,000 Shares of BioNTech (NASDAQ:BNTX) Stock - MarketBeat
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BioNTech's Oncology Ambitions Hinge on Landmark Data and Shareholder Vote () - aktiencheck.de
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
BioNTech's Pancreatic Cancer Vaccine Shows Unprecedented Long-Term Survival () - aktiencheck.de
BioNTech's Oncology Pipeline Delivers Critical Data as Strategic Pivot Accelerates () - aktiencheck.de
BNTX Earnings History & Surprises | EPS & Revenue Results | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch - TipRanks
Lbp Am Sa Acquires 15,255 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Impfung: Between Pandemic Legacy and Oncology Pivot, Future Hinges on Pipeline Wins - AD HOC NEWS
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings - Yahoo Finance
BioNTech SE Sponsored ADR $BNTX Shares Sold by Baillie Gifford & Co. - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IDEAYA Biosciences (IDYA), BioNTech SE (BNTX) and Stryker (SYK) - The Globe and Mail
BioNTech's Cancer Drug Data Fuels Optimism Amid Financial Headwinds () - aktiencheck.de
Net income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.20%
2.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):